How to control nighttime symptoms in patients with gastroesophageal reflux disease? Review article
Article Sidebar
Published:
Mar 31, 2024
Keywords:
gastroesophageal reflux disease, nocturnal gastric acid breakthrough, proton pump inhibitors, H2-receptor antagonists
Main Article Content
Abstract
In 80% of patients with gastroesophageal reflux disease, symptoms such as heartburn and regurgitation also occur during nighttime hours. The nocturnal form of GERD predisposes to the development of complications such as erosive esophagitis, esophageal ulcers and strictures, Barrett’s esophagus and esophageal adenocarcinoma. Therapeutic management, in addition to lifestyle modifications, includes pharmacotherapy using proton pump inhibitors and H2 receptor antagonists.
Article Details
How to Cite
Gąsiorowska, A. (2024). How to control nighttime symptoms in patients with gastroesophageal reflux disease?. Medycyna Faktow (J EBM), 17(1(62), 115-118. https://doi.org/10.24292/01.MF.0124.18
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Nirvan JS, Hasan SS, Babar ZUD et al. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis. Sci Rep. 2020; 10: 5814.
2. Ziółkowski BA, Pacholec A, Kudlicka M et al. Epidemiologia dolegliwości brzusznych w polskiej populacji. Prz Gastroenterol. 2012; 7(1): 20-5.
3. Gyawali CP, Yadlapati R, Fass R et al. Update to the modern diagnosis of GERD: the Lyon Consensus 2.0. Gut. 2024; 73: 361-71.
4. Shaker R, Castell DO, Schoenfeld PS et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003; 98(7): 1487-93.
5. Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009; 7(4): 372-8.
6. Shibli F, Skeans J, Yamasaki T et al. Nocturnal gastroesophageal reflux disease (GERD) and sleep an important relationship that is commonly overlooked. J Clin Gastroenterol. 2020; 54: 663-74.
7. Orr WC. Sleep and gastroesophageal reflux: what are the risks? Am J Med. 2003; 115(suppl 3A): 109-13.
8. Bredenoord AJ, Hemmink GJ, Smout AJ. Relationship between gastro-oesophageal reflux pattern and severity of mucosal damage. Neurogastroenterol Motil. 2009; 21(8): 807-12.
9. Lim KG, Morgenthaler TI, Katzka DA. Sleep and nocturnal gastroesophageal reflux. An update. Chest. 2018; 154(4): 963-71.
10. Schuitenmaker JM, Kuipers T, Smout AJPM et al. Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux. Neurogastroenterol Motil. 2022; 34: e14385.
11. Świdnicka‑Siergiejko A, Marek T, Waśko‑Czopnik D et al. Postępowanie diagnostyczno‑terapeutyczne w chorobie refluksowej przełyku. Konsensus\ Polskiego Towarzystwa Gastroenterologii 2022. Med Prakt. 2022; 6: 38-74.
12. Peghini PL, Katz PO, Bracy NA et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998; 93: 763-7.
13. Katz PO, Anderson C, Khoury R et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998; 12: 1231-4.
14. Adachi K, Komazawa Y, Fuishiro H et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol. 2003; 38: 830-5.
15. Fackler WK, Ours TM, Vaezi MF et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002; 122: 625-32.
16. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004, 16: 441-3.
17. Ours TM, Fackler WK, Richter JE et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003; 98: 545-50.
18. Xue S, Katz PO, Banerjee P et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001; 15: 1351-6.
19. Nwokolo CU, Smith JT, Gavey C et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther. 1990; 4(suppl 1): 29-45.
20. Wang Y, Pan T, Wang Q et al. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough (Review). Cochrane Database Syst Rev. 2009; (4): CD004275.
2. Ziółkowski BA, Pacholec A, Kudlicka M et al. Epidemiologia dolegliwości brzusznych w polskiej populacji. Prz Gastroenterol. 2012; 7(1): 20-5.
3. Gyawali CP, Yadlapati R, Fass R et al. Update to the modern diagnosis of GERD: the Lyon Consensus 2.0. Gut. 2024; 73: 361-71.
4. Shaker R, Castell DO, Schoenfeld PS et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003; 98(7): 1487-93.
5. Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009; 7(4): 372-8.
6. Shibli F, Skeans J, Yamasaki T et al. Nocturnal gastroesophageal reflux disease (GERD) and sleep an important relationship that is commonly overlooked. J Clin Gastroenterol. 2020; 54: 663-74.
7. Orr WC. Sleep and gastroesophageal reflux: what are the risks? Am J Med. 2003; 115(suppl 3A): 109-13.
8. Bredenoord AJ, Hemmink GJ, Smout AJ. Relationship between gastro-oesophageal reflux pattern and severity of mucosal damage. Neurogastroenterol Motil. 2009; 21(8): 807-12.
9. Lim KG, Morgenthaler TI, Katzka DA. Sleep and nocturnal gastroesophageal reflux. An update. Chest. 2018; 154(4): 963-71.
10. Schuitenmaker JM, Kuipers T, Smout AJPM et al. Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux. Neurogastroenterol Motil. 2022; 34: e14385.
11. Świdnicka‑Siergiejko A, Marek T, Waśko‑Czopnik D et al. Postępowanie diagnostyczno‑terapeutyczne w chorobie refluksowej przełyku. Konsensus\ Polskiego Towarzystwa Gastroenterologii 2022. Med Prakt. 2022; 6: 38-74.
12. Peghini PL, Katz PO, Bracy NA et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998; 93: 763-7.
13. Katz PO, Anderson C, Khoury R et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998; 12: 1231-4.
14. Adachi K, Komazawa Y, Fuishiro H et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol. 2003; 38: 830-5.
15. Fackler WK, Ours TM, Vaezi MF et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002; 122: 625-32.
16. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004, 16: 441-3.
17. Ours TM, Fackler WK, Richter JE et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003; 98: 545-50.
18. Xue S, Katz PO, Banerjee P et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001; 15: 1351-6.
19. Nwokolo CU, Smith JT, Gavey C et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther. 1990; 4(suppl 1): 29-45.
20. Wang Y, Pan T, Wang Q et al. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough (Review). Cochrane Database Syst Rev. 2009; (4): CD004275.